Literature DB >> 12826043

An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer.

E Greimel1, A Bottomley, A Cull, A-C Waldenstrom, J Arraras, L Chauvenet, B Holzner, K Kuljanic, J Lebrec, S D'haese.   

Abstract

This study defines the psychometric properties of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life (QOL) questionnaire designed to measure the QOL of patients with ovarian cancer. The ovarian cancer module (EORTC QLQ-OV28) was developed to supplement the EORTC QLQ-C30. The core questionnaire and the QLQ-OV28 were prospectively administered to 368 ovarian cancer patients after they had been treated with radical or debulking surgery followed by chemotherapy. The QLQ-OV28 module assesses abdominal/gastrointestinal symptoms, peripheral neuropathy, other chemotherapy side-effects, hormonal/menopausal symptoms, body image, attitude to disease/treatment and sexual functioning. Questionnaires were well accepted by patients, baseline compliance rates were 86%, 72% provided a second assessment, less than 3% of the items had missing data. Multi-trait scaling analyses confirmed the hypothesised scales. All hypothesised scales exhibited good psychometric properties. These results support the clinical and psychometric validity of the EORTC QLQ-OV28 module as a supplement to the EORTC QLQ-C30.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12826043     DOI: 10.1016/s0959-8049(03)00307-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  52 in total

1.  Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.

Authors:  Martin R Stockler; Felix Hilpert; Michael Friedlander; Madeleine T King; Lari Wenzel; Chee Khoon Lee; Florence Joly; Nikolaus de Gregorio; José Angel Arranz; Mansoor Raza Mirza; Roberto Sorio; Ulrich Freudensprung; Vesna Sneller; Gill Hales; Eric Pujade-Lauraine
Journal:  J Clin Oncol       Date:  2014-03-31       Impact factor: 44.544

2.  A pilot study of population-based, patient-reported outcome collection in cancer survivors.

Authors:  Veenoo Agarwal; Nadia Corsini; Marion C Eckert; Greg Sharplin; Imogen Ramsey; Kate Gunn; Michael K Fitzgerald; Bogda Koczwara
Journal:  Support Care Cancer       Date:  2021-01-07       Impact factor: 3.603

3.  Changes in short-term health-related quality of life in women undergoing gynecologic oncologic laparotomy: an associated factor analysis.

Authors:  Lucas Minig; Jorge Iván Vélez; Edward L Trimble; Roberto Biffi; Angelo Maggioni; Diana D Jeffery
Journal:  Support Care Cancer       Date:  2012-08-29       Impact factor: 3.603

4.  Distress screening remains important during follow-up after primary breast cancer treatment.

Authors:  Floortje K Ploos van Amstel; Sanne W van den Berg; Hanneke W M van Laarhoven; Marieke F M Gielissen; Judith B Prins; Petronella B Ottevanger
Journal:  Support Care Cancer       Date:  2013-03-01       Impact factor: 3.603

5.  Development and evaluation of Korean version of Quality of Sexual Function (QSF-K) in healthy Korean women.

Authors:  Yumi Lee; Myong Cheol Lim; Yedong Son; Jungnam Joo; KiByung Park; Jung-Sup Kim; Dong Ock Lee; Sang-Yoon Park
Journal:  J Korean Med Sci       Date:  2014-05-30       Impact factor: 2.153

6.  A prospective study of quality of life in patients undergoing pelvic exenteration: interim results.

Authors:  Youssef A Rezk; Karen E Hurley; Jeanne Carter; Fanny Dao; Bernard H Bochner; Janice J Aubey; Aileen Caceres; M Heather Einstein; Nadeem R Abu-Rustum; Richard R Barakat; Vicky Makker; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2012-10-09       Impact factor: 5.482

7.  A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.

Authors:  Michelle K Wilson; Michael L Friedlander; Florence Joly; Amit M Oza
Journal:  Oncologist       Date:  2017-11-08

8.  Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: results of a phase I and II study.

Authors:  Dominique Koensgen; Guelten Oskay-Oezcelik; Ioanna Katsares; Ulla Walle; Christine Klapp; Alexander Mustea; Dirk Stengel; Franz Porzsolt; Werner Lichtenegger; Jalid Sehouli
Journal:  Support Care Cancer       Date:  2009-09-17       Impact factor: 3.603

9.  Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer.

Authors:  Mary H Sailors; Diane C Bodurka; Ibrahima Gning; Lois M Ramondetta; Loretta A Williams; Tito R Mendoza; Sonika Agarwal; Charlotte C Sun; Charles S Cleeland
Journal:  Gynecol Oncol       Date:  2013-05-15       Impact factor: 5.482

Review 10.  Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials.

Authors:  Kristine A Donovan; Heidi S Donovan; David Cella; Martha E Gaines; Richard T Penson; Steven C Plaxe; Vivian E von Gruenigen; Deborah Watkins Bruner; Bryce B Reeve; Lari Wenzel
Journal:  J Natl Cancer Inst       Date:  2014-07-08       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.